1. Home
  2. IOVA

IOVA

Iovance Biotherapeutics Inc.

Logo Iovance Biotherapeutics Inc.

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

as 04-24-2024 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Founded: 2007 Country:
United States
United States
Employees: N/A City: SAN CARLOS
Market Cap: 3.2B IPO Year: N/A
Target Price: $25.64 AVG Volume (30 days): 9.0M
Analyst Decision: Strong Buy Number of Analysts: 11
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.89 EPS Growth: N/A
52 Week Low/High: $3.21 - $18.33 Next Earning Date: 05-07-2024
Revenue: $1,189,000 Revenue Growth: N/A
Revenue Growth (this year): 13820.1% Revenue Growth (next year): 157.99%

Share on Social Networks: